Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taligen Therapeutics, a company engaged in the discovery and development of novel protein therapeutics, has appointed Jeffrey Walsh as its chief business officer. The company has also appointed Christopher Horvath as vice president of preclinical sciences and Marie Green as senior program executive.
Subscribe to our email newsletter
Mr Walsh will contribute to the development of the company’s overall business strategy and oversee finance, legal, business development and general business operations. He has spent more than 20 years in leadership roles in the pharmaceutical and biotechnology industries with a focus on corporate finance, strategic planning and business development while at Inotek Pharmaceuticals, Exact Sciences, Pathogenesis (now part of Novartis), and SmithKline Beecham (now part of GlaxoSmithKline).
Dr Horvath will drive the transition of basic research emerging from Dr Holers’s laboratory into the development phase. He will oversee pharmacology, PK/PD, toxicology, pathology and biological assays. Dr Horvath has been responsible for non-clinical pharmacology and toxicology studies for a number of biologic compounds, including monoclonal antibody immunoconjugates and nucleic acids at Millennium Pharmaceuticals and Archemix.
Dr Green will lead Taligen’s development project teams for the company’s two most advanced clinical candidates, TT30 and TA106, across three potential indications: thrombotic microangiopathy, asthma and age-related macular degeneration. Most recently, Dr Green has led global project teams for several product candidates in different phases of development at Millennium Pharmaceuticals.
Abbie Celniker, CEO of Taligen Therapeutics, said: “I am pleased that Taligen has been able to attract the level of talent and experience that Mr Walsh, Dr Horvath and Dr Green bring to the company. We now have in place most of the key executives we believe are necessary to advance our lead clinical candidates through preclinical development to IND submission and to continue to advance Taligen’s growth plan.”